Bioventus, a provider of innovations for active healing, agreed to acquire the remaining 90% stake in CartiHeal, a provider of medical products and equipment, for $50m. "The robust data generated from the pivotal clinical trial, a randomized controlled trial with Agili-C, demonstrated superiority over surgical standard of care, microfracture and debridement, in KOOS overall compared to baseline. We believe this product could be a strong alternative for the approximately 650k US patients annually receiving microfracture or debridement along with other cartilage treatment options. In combination with our HA products, Agili-C represents an exciting potential new offering for our portfolio designed to address the spectrum of osteoarthritis disease," Alessandra Pavesio, Bioventus Senior Vice President and Chief Science Officer.